Weight-loss jabs are the latest craze for shedding a few pounds. Their effect has been dramatic with drugs such as Ozempic and Wegovy (semaglutide) causing users to lose up to 15% of their body fat on average.

Semaglutide, which is a glucagon-like peptide 1 (GLP-1 receptor agonist drug), mimics the action of a natural gut hormone which is released after we eat.

This gut hormone triggers multiple physiological responses that play a role in regulating body weight, such as releasing insulin to help control blood sugar levels, slowing stomach emptying (so we feel fuller for longer) and even telling the brain’s hunger centres to suppress appetite.

But as effective as GLP-1 drugs are, not everyone who uses them will lose a significant amount of weight. So-called “non-responders” are people who lose less than 5% of their body weight after roughly six months of treatment on the highest tolerated dose. Research suggests that between 10% and 30% of patients fit into this group.

Many people labelled as non-responders to GLP-1 receptor agonists such as semaglutide do not take the medication correctly or discontinue treatment before adequate therapeutic effect can be achieved. Studies show up to 20-60% of people people stop treatment within the first year, and widespread use of the drug in doses below the recommended amounts.

Certain metabolic issues such as insulin resistance, where the body’s cells........

© The Conversation